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Home mechanical ventilation (HMV) is increasingly used as a therapeutic option to patients
with symptomatic chronic hypoventilation. There is, however, a paucity of solid data on
factors that could affect prognosis in patients on home ventilation. In the present study,
our aim was to study several factors in these patients with potential influence on survival.
We examined 1526 adult patients from a nationwide HMV register to which data had been
reported prospectively for 10 years. The patients constituted a broad diagnostic spectrum
and the primary outcome in this study was death.
We found by far the poorest survival rate in the ALS patients with only 5% alive after 5
years. Among the other patient groups the survival pattern was more uniform and the
scoliosis, polio and Pickwick patients presented the best survival rate, after 5 years being
around 75%. No factors were associated with a greater hazard for death in the ALS
patients; in the non-ALS patients, however, negative predictors for survival were age,
concomitant use of oxygen therapy, tracheostomy ventilation and start of ventilatory
support in an acute clinical setting. Center size or county specific home ventilation
treatment prevalence did not affect survival.
In conclusion, in a large material of patients on HMV we found by far the poorest survival in
the ALS patients. In the non-ALS patients a number of patient-related factors affected
survival, while the size of the treating center or the regional treatment prevalence
did not.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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d.lu.se (B. Midgren).Introduction
One important outcome of home mechanical ventilation
(HMV) is survival. It has been suggested that HMV can
prolong survival and improve quality of life in neuromuscular
and chest wall disorders,1–5 whereas it may reduce
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Survival in HMV 1075symptoms of nocturnal hypoventilation and breathlessness
in other situations.6 A consensus that HMV should be offered
as a therapeutic option to patients with symptomatic
chronic hypoventilation appears to prevail in the field
although there are few randomized controlled trials to
support this.
Some guidance regarding the usefulness of HMV can be
derived from studies comparing survival with respect to
diagnosis.7–10 There are however but a few studies compar-
ing survival as regards patient related factors such as
physiological and clinical data.3,9 The impact of caregiver
related factors such as center size and regional treatment
prevalence has only scarcely been addressed in previous
studies.9,11
We wished to examine the relationship between survival
(with diagnosis, age and gender taken into consideration) on
the one hand and clinical features and method of receiving
HMV on the other. We also asked if the size of the treating
center and the HMV treatment prevalence in the county did
impact survival as a possible evidence of differences in
caregiver experience. We hypothesized that larger center
size and/or higher treatment prevalence would be asso-
ciated with longer survival.Methods
Our database was the Swedish HMV Register.12,13 Inclusion
criteria: all Swedish patients prescribed long-term ventila-
tion for domiciliary use. Patients using only CPAP for any
purpose or ventilators for physiotherapy only were not
included. For patients starting therapy after January 1, 1996
we prospectively register data on inter alia blood gases,
concomitant oxygen therapy, ventilator interface, mode and
daily duration of therapy, and acute vs. elective initiation of
HMV. The register continuously obtains data on vital status
and the dates of death from the Swedish Population
Register.
In this study we analyzed only patients over the age of 18
years when starting HMV ðN ¼ 1526Þ during the 10-year
period 1996–2005. The primary outcome in this study was
death (before March 15, 2006).
In the preliminary analysis of survival we divided the
patients according to the underlying diagnoses into eight
groups: 1. Pickwickian (in the register defined as sleep
apnea syndrome with respiratory insufficiency), 2. pulmon-
ary disease (66% COPD patients), 3. neurological disease
other than amyotrophic lateral sclerosis (ALS), i.e. mainly
patients with progressive neuromuscular disease (88%), 4.
ALS, 5. post-poliomyelitis syndrome, 6. scoliosis, 7. tuber-
culosis sequelae (TBC) and finally 8. other diseases, a group
consisting of patients with high cervical lesions, central
hypoventilation and a medley of other diagnoses. In view of
the pronounced difference in survival between the ALS and
non-ALS patients and the small differences within the latter
group, we joined the non-ALS patients as one group for
further analyses.
Among the nearly 50 clinics that manage the treatment of
HMV patients, we arbitrarily label as ‘‘big centers’’ those six
clinics who reported more than 100 patients starting HMV
during the 10 years inclusion period. These centers cared for
55% of the HMV patients. For at least 8 years from registerstart, four counties out of the 26 counties in Sweden,
(henceforward referred to as ‘‘top counties’’), consistently
presented a much higher HMV treatment prevalence
compared to the rest.13 In these counties lived 26% of the
HMV patients. At the time of this analysis the top counties
had a treatment prevalence of 22 per 100.000 in contrast to
14 for the rest.
The Swedish Data Inspection Board has approved the
register and the Medical Ethics Committee at the University
of Lund has approved the study. For statistical analyses we
used the software STATISTICA version 7.1 to generate
descriptive data and compile regression models and graphs.
Cox’s proportional hazards regression model was used to
assess the effects of patient and caregiver related factors on
survival. P values less than 0.05 were considered as
significant.Results
The majority (75%) of the patients was ventilated during
night-time only, 22% were ventilated 8–24 h/day and a small
proportion (3%) was ventilated in day-time only. Ventilatory
support was in all cases delivered by intermittent positive
pressure ventilators. From therapy start HMV was provided
as non-invasive ventilation (NIV) via a mask in 91% and as
tracheostomy invasive ventilation (TIV) in 6% (some missing
data). Still, in the patients starting HMV electively 2% only
were tracheostomized while this was the case in 19% of the
acute patients. Information on transition from NIV to TIV (or
the opposite) does not with certainty reach the register.
Demographic information and the distribution of patient/
caregiver related factors in the diagnostic groups are
displayed in Table 1. Although the Pickwick group is by far
the biggest of the eight diagnostic groups the neurological
patients including ALS patients make a total of almost the
same quantity as the Pickwick patients.
The distribution of the patient-related factors with
respect to the two caregiver related factors are shown in
Table 2. It can be seen that acute start of HMV and the use of
concomitant oxygen were more frequent in small centers
and in the counties with low HMV prevalence. Counties with
low prescription rates of HMV also had a higher proportion of
tracheostomies.
The survival of the entire material is shown in a
Kaplan–Meier plot in Fig. 1. The ALS patients are evidently
different from all other groups by having the poorest
survival rate at all times; that is a probability to survive
after 2 years of 20% and after 5 years of just above 5%. The
relative risk for death in the ALS patients compared to all
other patients was 8.02 (CI 6.48–9.92, Po0:001).
Among the remaining groups the pattern is more uniform;
still, mutual differences are present e.g. the TBC patients’
relative risk for death compared to the scoliosis patients was
1.91 (95% CI: 1.25–2.90, Po0:01).
The relationship between survival and the singled out
patient and caregiver related factors when starting HMV is
shown in Tables 3 and 4. Table 3 displays the univariable
analyses for each factor in the ALS and non-ALS groups. None
of the factors significantly affected survival in the ALS
patients, we, therefore, proceeded to multivariable analysis
in the non-ALS patients only (Table 4).
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Table 1 Primary data in 1526 adults starting HMV.
Pickwick Pulmonary Neuromusc ALS Post-polio Scoliosis TBC Other
N (% of all patients) 422 (28) 251 (16) 224 (15) 165 (11) 141 (9) 123 (8) 98 (6) 102 (7)
Start age (SD) 61 (11.2) 63 (11.5) 49 (16.2) 64 (10.5) 67 (9.1) 62 (13.2) 73(6.0) 56 (16.2)
Age475 years (%) 7 11 3 13 18 18 41 12
Male gender (%) 56 37 58 68 48 36 41 58
PaCO2 (SD) 7.1 (1.3) 7.7 (1.6) 7.3 (1.7) 6.6 (1.4) 7.1 (1.3) 7.5 (1.3) 7.6 (1.0) 7.2 (1.6)
PaO2 (SD) 7.5 (1.5) 7.4 (1.8) 9.0 (2.0) 9.7 (1.7) 8.3 (1.4) 7.7 (1.8) 7.4 (1.3) 8.0 (2.2)
PaO2o7.4 kPa (%) 49 53 22 8 22 42 49 37
Acute start (%) 31 33 32 17 19 27 19 39
TIV (%) 1 4 19 4 8 3 2 21
Big center (%) 53 54 57 70 57 44 61 44
Top county (%) 33 31 25 10 12 24 43 19
Arterial blood gases were obtained in elective patients only. Big center (%) is the fraction of the patients cared for by big centers. Top
county (%) is the fraction of the patients living in one of the four high treatment prevalence counties.
TIV: tracheostomy invasive ventilation.
Table 2 Percentage distribution of patient-related
factors at HMV initiation with respect to the two
caregiver related factors.
Big center Top county
Yes No Yes No
Age475 years 12 12 14 12
Male gender 54 48 53 51
Concomitant O2 15 31*** 15 25***
PaO2o7.4 kPa 40 37 43 37
Acute start 22 37*** 24 30*
TIV 6 8 3 8**
TIV: tracheostomy invasive ventilation.
*Po0.05.
**Po0.01.
***Po0.001.
Table 3 Univariable analyses of relative risk for death
in the ALS and non-ALS patients.
ALS Non-ALS
Age475 years
1.30 2.05***
0.77–2.21 1.61–2.62
Male gender
0.79 0.92
0.54–1,16 0.76–1.10
Concomitant O2
2.0 1.85***
0.89–4.61 1.52–2.25
PaO2o7.4 kPa
0.78 1.27*
0.31–1.98 1.04–1.56
Acute start
1.29 1.76***
0.83–2.03 1.45–2.13
TIV
0.70 1.51**
0.28–1.71 1.12–2.03
Big center
1.31 0.86
0.88–1.95 0.72–1.03
Top county
1.02 1.13
0.59–1.75 0.93–1.37
Each cell shows on top the hazard ratio and below the 95%
confidence intervals.
TIV: tracheostomy invasive ventilation.
*Po0.05.
**Po0.01.
***Po0.001.
Figure 1 Probability to survive in 1526 adult patients after
starting HMV.
M. Laub, B. Midgren1076As seen age was a significant factor for survival while
gender was not. Among the patient related factors we found
that concomitant oxygen therapy, TIV and acute start of HMV
were independently associated with worse survival. Con-
cerning the two caregiver-related factors we found no
relationship to survival.
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Table 4 Multivariable analyses of relative risk for death
in the non-ALS patients.
Age475 years 2.05***
1.55–2.70
Male gender 1.06
0.86–1.31
Concomitant O2 1.63***
1.27–2.10
PaO2o7.4 kPa 1.04
0.83–1.30
Acute start 1.79***
1.19–2.70
TIV 1.79**
1.19–2.68
Big centre 1.03
0.83–1.27
Top county 1.22
0.97–1.52
Each cell shows on top the hazard ratio and below the 95%
confidence intervals.
TIV: tracheostomy invasive ventilation.
*Po0.05.
**Po0.01.
***Po0.001.
Survival in HMV 1077Discussion
From a large material of adult patients on HMV recorded
prospectively in a national register we have in this report
presented 10-year survival data. We have shown that
patients suffering from ALS at all times distinctly had the
poorest probability to survive. Among the remaining patient
groups differences in survival could be pointed out, the best
long-term survival rates being twice as good as the poorest,
but the overall picture was relatively homogeneous. We
have, therefore, with respect to impact factors on survival
analyzed them as one group. Although this may be an
oversimplification, it enables us to perform these analyses in
a much larger and more comprehensive material. We looked
at a number of patient related factors when HMV was
launched and in the non-ALS patients we found that use of
concomitant oxygen, TIV and start in an acute clinical
setting were factors which were associated with a greater
hazard for death. Although there were differences in clinical
practice between small and big centers and between high
and average prevalence counties, these differences seemed
to have no effects on survival.
In ALS previous studies have stated varying survival rates.
In an early series of 101 patients14 survival rates were 69% at
2 years and 33% at 5 years. These are considerably higher
rates compared with more recent smaller studies and our
report. Part of an explanation of this may be that all
patients were on TIV, whereas this only applies to 5% of our
ALS patients (at therapy start). TIV may be preferable in
patients with severe paralyses, especially of bulbar nature.
We also speculate that caregivers and relatives may be more
hesitant to withdraw TIV than NIV.15 In another study16
including 122 patients, 38 used NIV more than 4 h/day and
had a survival rate after 2 years just below 20%, which isvery close to the findings in our study. In a control group
consisting of 52 patients who renounced ventilatory support,
none were alive after 2 years. In a recent study3 one group
of ALS patients showed a survival rate similar to our findings,
while survival was better in another group that underwent
early systematic respiratory evaluation (a caregiver related
factor). In our study we were unable to demonstrate any
factors affecting survival in the ALS patients, besides the
diagnosis itself. This indicates that the rapid loss of motor
neuron function in ALS overshadows the relatively strong
prognostic factors in the non-ALS group.
Hypoxia as well as need of concomitant oxygen have
previously been depicted as factors that were related to
poor survival in HMV.9,17 We could not confirm that hypoxia is
a significant factor probably because hypoxia in many cases
is corrected by HMV.18 On the other hand, we could confirm
that the use of concomitant oxygen was associated with
worse prognosis indicating that these two factors are not
equivalent. The use of concomitant oxygen may reflect a
component of pulmonary parenchymal disease (with worse
prognosis). However, the interpretation that it reflects
suboptimal ventilator therapy remains a possibility. Smaller
centers with less experience may be more prone to correct
hypoxemia with oxygen than to adjust the ventilator
settings to achieve the desired therapy goal. Furthermore,
launch of HMV in an acute clinical setting involved a greater
risk for death, a fact Duiverman et al.10 found in a
miscellaneous group of 20 mainly TBC patients as well.
An explanation of why acute start of HMV, use of
concomitant oxygen and TIV were more frequent in small
centers and in the counties with low HMV prevalence may be
that clinical procedures and followup prior to HMV start
were less extensive compared to that in big centers or top
counties. This may result in more patients embarking on
ventilatory support in an emergent situation and in turn
entailing more patients starting this as TIV. Need of
concomitant oxygen at HMV start may be related to this
scenario or may reflect suboptimal ventilator therapy as
discussed above.
Most studies of to day report outcome of HMV delivered as
NIV. In this study, 98 patients (6%) from start were embarked
upon TIV and this was coupled with a greater risk for death,
which may not be surprising as one might claim that the
disease severity was more profound in these patients. On
the other hand, as we discussed above in the ALS patients,
tracheostomy per se should not necessarily imply shorter
survival and in some patients TIV is more feasible compared
to NIV. Post polio and scoliosis patients on TIV have,
furthermore, been reported to perceive better health
compared to NIV for these diagnoses.19 It is, however, a
weakness of our study that the register contain no certain
documentation on transition from NIV to TIV, yet our
assumption is that this was performed in less than 10% of
all patients and most often in the neurological patients.
One could expect that treatment in big centers with a
much greater patient flow or in centers with more consistent
followup procedures resulted in a better outcome, but in our
report this was not the case. One study has shown a possible
connection to consistent procedures9 as the survival was
better in the patients (primarily on LTOT) with complete
data of respiratory function. On the other hand, if the
patient selection in the centers is biased according to local
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might have worked up a somewhat uniform quality of care
for the patients once HMV has been started. We have,
furthermore, previously shown13 that with regard to elective
patients the counties with high treatment prevalence had as
strict indications to launch HMV as all other counties,
demonstrating that disease severity at HMV launch is quite
homogeneous in Sweden. As regards center size and
treatment prevalence our hypothesis was that ‘‘big is
better’’, a notion we can turn down and recast to ‘‘size
doesn’t matter’’.
In conclusion, in a large material of adult HMV patients,
the ALS group had by far the poorest survival rate. Survival
was roughly in line with that in previous studies and
predictors of increased risk for death in non-ALS patients
were greater age, use of supplemental oxygen treatment,
tracheostomy ventilation and launch of HMV in an emergent
clinical setting. The relative risk for death was not affected
by the size of the treating center and the treatment
prevalence in the county.
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